This is the first report to show an impaired IFN-α response via TLR3/RIG-I and TLR7/8 in T2DM patients prescribed metformin, whereas only via TLR7/8 in those prescribed glibenclamide. This evidence concerns the gene TLR7 and type 2 diabetes mellitus.